No Data
No Data
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Rigel Pharmaceuticals (RIGL), as it has been recently upgraded to a Zacks Rank #2 (Buy).
US$5.15 - That's What Analysts Think Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Is Worth After These Results
The analysts might have been a bit too bullish on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), given that the company fell short of expectations when it released its first-quarter results last week.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Express News | Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
No Data